Bayesian Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-36,000
| Closed | -$585K | – | 643 |
|
|
2024
Q2 | $585K | Buy |
+36,000
| New | +$585K | 0.07% | 329 |
|
|
2023
Q3 | – | Sell |
-11,837
| Closed | -$283K | – | 666 |
|
|
2023
Q2 | $283K | Buy |
11,837
+337
| +3% | +$8.07K | 0.03% | 556 |
|
|
2023
Q1 | $216K | Buy |
+11,500
| New | +$216K | 0.03% | 590 |
|
|
2022
Q3 | – | Sell |
-41,696
| Closed | -$587K | – | 664 |
|
|
2022
Q2 | $587K | Buy |
+41,696
| New | +$587K | 0.11% | 285 |
|
|
2020
Q1 | – | Sell |
-5,900
| Closed | -$252K | – | 755 |
|
|
2019
Q4 | $252K | Buy |
+5,900
| New | +$252K | 0.04% | 475 |
|
|
2017
Q4 | – | Sell |
-25,584
| Closed | -$964K | – | 528 |
|
|
2017
Q3 | $964K | Buy |
+25,584
| New | +$964K | 0.23% | 137 |
|
|
2017
Q1 | – | Sell |
-14,800
| Closed | -$427K | – | 384 |
|
|
2016
Q4 | $427K | Buy |
+14,800
| New | +$427K | 0.11% | 340 |
|